José L. Toro, Director, Lachman Consultants, wrote a recent article for Contract Pharma about improving the bioavailability and therapeutic efficiency of poorly soluble drugs.
Here is a brief excerpt from the article: “Over forty percent (40%) of new chemical entities (NCEs) that are being developed confront the challenge of being poorly soluble in water. These include many anti-cancer drugs, such as monoclonal antibodies and small molecules which are also anti-cancer drugs. The problem with NCEs that are poorly soluble in water is their poor absorption and low bioavailability. Anti-cancer drugs exhibit low water solubility due in part to their large molecular weight.”
